Yuzhu Cheng Selected Research

4- (6- cyclohexylmethoxy- 9H- purin- 2- ylamino)- N,N- diethylbenzamide

9/2005

Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin down-regulation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yuzhu Cheng Research Topics

Disease

4	Neoplasms (Cancer) 01/2021 - 09/2005
1	Hyperinsulinism (Hyperinsulinemia) 01/2018
1	Body Weight (Weight, Body) 01/2018
1	Insulin Resistance 01/2018
1	Obesity 01/2018
1	Carcinoma (Carcinomatosis) 09/2005
1	Ovarian Neoplasms (Ovarian Cancer) 09/2005

Drug/Important Bio-Agent (IBA)

1	Tumor Biomarkers (Tumor Markers)IBA 01/2021
1	Liposomes (Liposome)IBA 01/2019
1	Glucose (Dextrose)FDA LinkGeneric 01/2018
1	Hydroxysteroid DehydrogenasesIBA 01/2018
1	Islet Amyloid PolypeptideIBA 01/2018
1	C-PeptideIBA 01/2018
1	CorticosteroneIBA 01/2018
1	Insulin (Novolin)FDA Link 01/2018
1	Proteins (Proteins, Gene)FDA Link 01/2018
1	Cyclin-Dependent Kinase 2IBA 09/2011
1	ProdrugsIBA 09/2011
1	NU6102IBA 09/2011
1	6- ((3- chloro)anilino)- 2- (isopropyl- 2- hydroxyethylamino)- 9- isopropylpurineIBA 09/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 09/2005
1	Caspase 3 (Caspase-3)IBA 09/2005
1	4- (6- cyclohexylmethoxy- 9H- purin- 2- ylamino)- N,N- diethylbenzamideIBA 09/2005
1	SurvivinIBA 09/2005
1	Caspase 9IBA 09/2005

Therapy/Procedure

1	Immunotherapy 01/2021
1	Therapeutics 09/2005